WYRGRLC
WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1027630-05-2
- Formule: C43H64N14O9S
- Masse moléculaire:953.12
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
WYRGRLC (0-1 μM) potently and sequence-specifically inhibits the binding of phage displaying WYRGRL to bovine cartilage, with an IC50 of 140 nM[1].
WYRGRLC (15 mg; 1 h) specifically binds to type II collagen α1 chain, which is an abundant extracellular matrix protein in bovine cartilage[1].
WYRGRLC-modified C6@PEG-PA@P-Lipo enhances targeted cellular uptake by rat chondrocytes (RCCs)[2].
WYRGRLC-modified P-Lipo can adhere to the surface layer of porcine cartilage tissue, but its deep penetration ability is limited due to its large particle size[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male SD rats (210-230 g)[2]
-
Dosage:100 μL
-
Administration:intra-articular injected, once
-
Result:Enabled prolonged joint retention of the RP@PEG-PA@P-Lipo delivery system, contributing to effective suppression of synovitis, preservation of cartilage structure and metabolism, and reduction of chondrocyte apoptosis.
Chemical Information
-
CAS No. 1027630-05-2
-
Masse moléculaire 953.12
-
Formule C43H64N14O9S
-
Sequence
Trp-Tyr-Arg-Gly-Arg-Leu-Cys
-
Sequence Shortening
WYRGRLC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Rothenfluh DA, et al. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater. 2008;7(3):248-254. [Content Brief]
[2]. Lin G, et al. Enhancing retention and permeation of rapamycin for osteoarthritis therapy using a two-stage drug delivery system. Mater Today Bio. 2024;29:101279. Published 2024 Sep 28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WYRGRLC Related Classifications
HY-P10739C Related Classifications
Powered by Bioz